ribociclib
novartis
['kisqali']
in patients with visceral metastases including liver metastases and multiple metastatic sites, the overall survival was 62.7 months in patients on #kisqali plus endocrine therapy compared to 52.1 months in patients on endocrine therapy alone
#esmo22 #esmo2022 #onctwitter
iPharmaCenter is a #website which covers #pharmaceutical and #healthcare #news plus #blogs #diseases #drugs #healthcaresystems #globalhealth #pharma